2 Comments
User's avatar
Mark Neumann's avatar

Great interview. It seems that are biggest problems are pre-op and post-op: getting patients evaluated and on the wait list in a timely manner, and honoring their place on the list, and then having structured surveillance of the new graft to protect it and extend longevity. In a world where donated organs are a limited resource, I think solving those issues is imperative. Blending in MA patients in IOTA is also important; that 50% penetration will only get larger during the six years of this demonstration.

Expand full comment
Tim Fitzpatrick's avatar

Mark, thank you. Well said, I agree these seem to be biggest opportunities and unmet needs. I wasn't as familiar with how MA mix will work, so I'm hoping to explore that a bit further as things progress with IOTA.

Expand full comment